Trial result ·
Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This study tested a new drug called alixorexton in narcolepsy type 1. It was a phase 2 trial with 92 adults aged 18 to 70. People were put by chance into 4 groups. They took a 4 mg, 6 mg or 8 mg tablet, or a dummy pill. They took it by mouth once a day for 6 weeks. Neither the people nor the doctors knew who got which pill. The main test measured how long people could stay awake on a sleep test.
What they found
After 6 weeks, the dummy pill group stayed awake for 2·3 minutes on average. The drug groups stayed awake for 24·0, 25·9 and 28·2 minutes. Compared with the dummy pill, the gain was 22·2 to 26·0 minutes. Side effects more common on the drug included passing urine often. Others were trouble sleeping, extra saliva, urgent need to pee, blurred vision and sweating.
What it means for patients
The authors say the drug helped people with narcolepsy type 1 at 6 weeks. They report gains in staying awake, daytime sleepiness and cataplexy. They say the drug was generally well tolerated. The side effects fit with how this type of drug is known to act. The authors say a phase 3 trial is the next step.
Why it is not certain yet
This phase 2 trial had 92 people. The drug was compared with a dummy pill for just 6 weeks. An optional 7-week extension followed, but people then knew what they took. The abstract does not give results from that extension. The study was funded by Alkermes. The results still need testing in a phase 3 trial.
The registered trial
The paper names this trial from a public trial registry. Its page shows who the trial is for, its sites and its status.
Source
Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial.
PubMed · PMID 42636845We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Narcolepsy publications